Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M.

Crit Care Med. 1997 Jul;25(7):1115-24.

PMID:
9233735
2.

[IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy].

Fiocco U, Vezz├╣ M, Cozzi L, Todesco S.

Reumatismo. 2004 Jan-Mar;56(1 Suppl 1):62-73. Review. Italian.

3.
4.

Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock.

Mohammad RA.

Am J Health Syst Pharm. 2010 Aug;67(15):1238-45. doi: 10.2146/ajhp090325. Review.

PMID:
20651313
5.

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.

Zeni F, Freeman B, Natanson C.

Crit Care Med. 1997 Jul;25(7):1095-100. Review. No abstract available.

PMID:
9233726
6.

The interleukin-1 receptor antagonist and its delivery by gene transfer.

Evans CH, Robbins PD.

Receptor. 1994 Spring;4(1):9-15. Review.

PMID:
8038709
7.
8.

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.

Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A.

Crit Care. 2005;9(6):R607-22. Epub 2005 Sep 22. Review.

9.

[Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome].

Boermeester MA, van Leeuwen PA, Schneider AJ, Houdijk AP, Ferwerda CC, Wesdorp RI.

Ned Tijdschr Geneeskd. 1993 Feb 13;137(7):337-42. Review. Dutch. No abstract available.

PMID:
7679779
10.

New therapeutic approaches in sepsis: a critical review.

Eidelman LA, Pizov R, Sprung CL.

Intensive Care Med. 1995 Nov;21 Suppl 2:S269-72. Review. No abstract available.

PMID:
8636535
11.

Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies.

Kalil AC, Sun J.

Intensive Care Med. 2011 Mar;37(3):420-9. doi: 10.1007/s00134-010-2121-0. Epub 2011 Jan 18. Review.

PMID:
21243334
13.

Supplemental immune globulins in sepsis: a critical appraisal.

Werdan K, Pilz G.

Clin Exp Immunol. 1996 May;104 Suppl 1:83-90. Review.

14.

[Treatment of rheumatoid arthritis by interleukin-1 receptor antagonist].

Wendling D, Jorgensen C.

Rev Med Interne. 2002 Dec;23(12):1006-11. Review. French.

PMID:
12504237
15.

Modulation of cytokine responses in sepsis.

Lowry SF, Moldawer LL.

Ann N Y Acad Sci. 1993 Jun 23;685:471-82. Review. No abstract available.

PMID:
8363256
16.

[Therapeutic perspectives of severe infectious states].

Offenstadt G, Guidet B, Barakett V.

Rev Prat. 1993 Jan 1;43(1):59-64. Review. French.

PMID:
8469900
17.

Specific cytokine regulators and their therapeutic potentials--an overview.

Kashiwagi H, Suzuki H.

Intern Med. 1992 Nov;31(11):1245-9. Review. No abstract available.

18.

Sepsis trials. Intersection of investigation, regulation, funding, and practice.

Bernard GR.

Am J Respir Crit Care Med. 1995 Jul;152(1):4-10. Review. No abstract available.

PMID:
7599855
19.

The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.

Hall TC, Bilku DK, Al-Leswas D, Horst C, Dennison AR.

Ir J Med Sci. 2012 Mar;181(1):1-6. doi: 10.1007/s11845-011-0778-1. Epub 2011 Nov 8. Review.

PMID:
22065211
20.

Clinical sepsis trials.

Abraham E.

Chest. 1994 Mar;105(3 Suppl):53S-55S. Review. No abstract available.

PMID:
8131613

Supplemental Content

Support Center